CA-ALKIRA
27.4.2022 13:02:08 CEST | Business Wire | Press release
Cloud networking pioneer Alkira today launched Cloud Insights, a free tool to improve the networking and security of enterprise cloud deployments. Nearly a third (32%) of cloud spending is wasted, according to Flexera’s State of the Cloud Report 2022, which identifies optimization of existing cloud resources as the top priority for enterprises.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220427005119/en/
Cloud spending and network complexity accelerated during the pandemic, putting further pressure on businesses to optimize their cloud deployments. Growth shows no sign of slowing this year, as IDC forecasts a 21.7% increase in cloud infrastructure spending for the rest of 2022.
Alkira Cloud Insights helps cloud architects and networking admins regain control of their cloud infrastructure. The tool provides tailored recommendations on how to improve security, optimize spend and boost cloud networking performance in Amazon AWS and Microsoft Azure environments. It can help uncover duplicate IP addresses, unsanctioned internet access, unused networks and security resources, misconfigured security group settings, and unaccounted for shadow IT resources, among other things.
“Many organizations dramatically increased their cloud deployments at the beginning of Covid to support remote work and digital transformation,” said Amir Khan, CEO and founder of Alkira. “Because the shift was so sudden, many organizations' initial focus was on just making things work; the deployments were far from optimized. Alkira Cloud Insights allows businesses to do what equates to a bit of ‘spring cleaning’ for their environments. The tool helps to streamline cloud deployments, improve security posture and eliminate costly waste.”
Cloud Insights performs a rapid discovery of an organization’s AWS and Azure cloud networking environments. Companies will get a complete and automated inventory of their networking and security resources. They’ll also receive actionable data, including recommendations to improve cloud usage, security and spend. The insights and findings are delivered in an easy to use, centralized dashboard. There is also the ability to configure automated reporting to keep up to date on dynamic changes made to the cloud network environment.
Brad Casemore, Research Vice President, Datacenter and Multicloud Networks, IDC, said: “Networks that enable and support hybrid and multicloud should be sufficiently intelligent to perform optimally across an increasingly distributed landscape of cloud workloads and end points. But it all starts with meaningful audit and discovery, determining and understanding what workloads are running in which clouds, and providing insight into the networks and security postures associated with those workloads.
“Only with that foreknowledge can enterprises gain actionable insights that yield valuable business benefits and outcomes. With Cloud Insights, Alkira offers customers a free tool that helps to provide a foundational understanding of their cloud environments, setting the stage for informed enhancements that improve the agility, efficiency, performance, resiliency, and security of cloud networking.”
Existing customers get immediate access to Cloud Insights through the Alkira portal. The company is also making it freely available at https://www.alkira.com/cloud-insights to other enterprise teams looking for a quicker and easier way to audit their cloud estate.
About Alkira
Alkira is the leader in cloud networking as a service . We unify multiple clouds, sites, and users via an enterprise network built entirely in the cloud. Our Cloud Exchange Points auto-create this network plumbing and when deployed to multiple locations auto-connect to form a global fabric – all done with point and click integration of best-of-breed security and networking services. The network is managed using the same controls, policies, and security network admins know, can instantly scale as needed, and is available as a service. There is no new hardware to deploy, no software to download and no cloud architecture to learn. Alkira’s solution is trusted by Fortune 100 enterprises, leading system integrators and global managed service providers. Learn more at alkira.com and follow us @alkiranet .
Video Tour: https://youtu.be/jBQipdute44
View source version on businesswire.com: https://www.businesswire.com/news/home/20220427005119/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom